[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550233":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":83,"centralContacts":88,"locations":94,"responsibleParty":111,"collaborators":38,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":38,"eligibilityCriteria":119,"healthyVolunteers":115,"sex":120,"minAge":121,"maxAge":38,"enrollmentInfo":122,"targetDuration":38,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":38,"overallStatus":96,"whyStopped":38,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (Ga-68 PSMA-11, PET\u002FCT)","EXPERIMENTAL","Patients receive Ga-68 PSMA-11 IV and then undergo PET\u002FCT over 1 hour, 50-100 minutes after injection.",[13,14,15,16],"Procedure: Computed Tomography","Other: Electronic Health Record Review","Drug: Ga 68 PSMA-11","Procedure: Positron Emission Tomography",[18,34,39,71],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Computed Tomography","Undergo PET\u002FCT",[9],[24,25,26,27,28,29,30,31,32,33],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography",{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Electronic Health Record Review","Ancillary studies",[9],null,{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","Ga 68 PSMA-11","Contrast dye given IV",[9],[45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70],"(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC","(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC","(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","(68Ga)Glu-urea-Lys(Ahx)-HBED-CC","68Ga-DKFZ-PSMA-11","68Ga-HBED-CC-PSMA","68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC","68Ga-PSMA","68Ga-PSMA-11","68Ga-PSMA-HBED-CC","[68Ga] Prostate-specific Membrane Antigen 11","[68Ga]GaPSMA-11","AAA 517","AAA-517","AAA517","Ga PSMA","Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled PSMA-11","Ga 68 PSMA-11, Intravenous Solution","Gallium Ga 68 PSMA-11","Gallium Ga 68-labeled PSMA-11","Gallium-68 PSMA","Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC","GaPSMA","PSMA-HBED-CC GA-68",{"type":19,"name":72,"description":21,"armGroupLabels":73,"otherNames":74},"Positron Emission Tomography",[9],[75,76,77,78,79,80,81,82],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging","PT",[84],{"name":85,"affiliation":86,"role":87},"Brian J. Burkett, MD, MPH","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[89],{"name":90,"role":91,"phone":92,"phoneExt":38,"email":93},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[95],{"facility":86,"status":96,"city":97,"state":98,"zip":99,"country":100,"countryCode":101,"cosmosGeoPoint":102,"geoPoint":107,"contacts":108},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":103,"coordinates":104},"Point",[105,106],-92.4699,44.02163,{"lat":106,"lon":105},[109,110],{"name":90,"role":91,"phone":92,"phoneExt":38,"email":93},{"name":85,"role":87,"phone":38,"phoneExt":38,"email":38},{"type":112,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100550233","phase-2-an-investigational-scan-ga-68-psma-11-petct-for-detection-of-disease-recurrence-or-progression-in-patients-with-glioma-100550233",false,"NCT06444412","An Investigational Scan (Ga-68 PSMA-11 PET\u002FCT) for Detection of Disease Recurrence or Progression in Patients With Glioma","GA-68 PSMA-11 PET To Evaluate Malignant Glioma Recurrence - A Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* History of World Health Organization (WHO) grade III or IV infiltrating glioma previously treated with first-line chemoradiotherapy.\n* MRI findings compatible with contrast-enhancing recurrent infiltrating glioma.\n* Planned biopsy or resection of suspected disease recurrence.\n* Willing to sign release of information for any radiation and\u002For follow-up records.\n* Ability to provide informed written consent.\n* Ability to provide tissue for mandatory correlative research component.\n\nExclusion Criteria:\n\n* Unable to undergo a PSMA PET\u002FCT scan (e.g. body habitus, claustrophobia).\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of childbearing potential unwilling to employ adequate contraception","ALL","18 Years",{"count":123,"type":124},25,"ESTIMATED","INTERVENTIONAL",[127],"PHASE2","This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)\u002Fcomputed tomography (CT) imaging is useful in differentiating between disease that has come back after a period of improvement (recurrence) or that is growing, spreading, or getting worse (progression) and treatment effect in patients with glioma. Patients with glioma undergo frequent imaging for assessment of disease status. After first-line treatment however, the correlation between imaging findings and tumor activity can be confused, and surgery is often required for definitive diagnosis. The PET\u002FCT scanner is an imaging machine that combines 2 types of imaging in a single scan. The PET scanner detects and takes pictures of where the radioactive imaging agent (68Ga PSMA-11) has gone in the body and the CT scanner uses x-rays to take structural pictures inside the body. PSMA PET also binds to neoplastic blood vessels, including those in gliomas. This study may help researchers learn whether GA-68 PSMA-11 PET\u002FCT is useful for improving detection of tumor recurrence or progression, as opposed to treatment effects, in patients with gliomas.",[130,131],"WHO Grade 3 Glioma","WHO Grade 4 Glioma","2026-06-18",{"date":134,"type":135},"2026-06-22","ACTUAL",{"date":137,"type":135},"2026-01-12",{"date":139,"type":124},"2028-07-31",{"name":5,"class":6},1]